Genocea Biosciences Higher Off Positive Clinical Data, Favorable Analyst Comments

Genocea Biosciences Inc GNCA shares are trading higher by $0.38 (8 percent) at $4.92 in Thursday's session. There are two catalysts behind the rally.

First of all, the the company announced positive six-month results from GEN-003 Phase 2b clinical trial. That news prompted Cowen to come out positive on the issue, saying that it's "significantly undervalued."

After a higher open, the stock briefly traded over $5.00 before falling all the way to $4.32. That level was only a nickel away from Wednesday's low of $4.27. From that low, the issue rallied to make a new high for the session at $5.25. That high coincides with its October high of $5.22.

At this time, the issue is struggling to remain in the $5 handle.